Results 241 to 250 of about 410,880 (314)

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study. [PDF]

BMC Med
Liu J, Jiang M, Zhang M, Zhou S, Li M, Shi X, Li L, Yang X, Li P, Tian M, Ma F, Xu B, Li Q.   +12 more
europepmc   +1 more source

GLS1 Orchestrates Exosome‐Mediated Tumor‐Endothelial Communication to Facilitate Angiogenesis

Advanced Science, EarlyView.
This study reveals a previously unappreciated, non‐metabolic function of GLS1 in the control of tumor angiogenesis via exosome‐mediated CAV1‐TNC signaling, indicating that therapeutic targeting of GLS1 may offer a dual benefit by simultaneously suppressing tumor metabolic activity and angiogenic processes in head and neck cancer. ABSTRACT Glutaminase 1
Jianqiang Yang, Zhenzhen Fu, Fanghui Chen, Soumya Vijaya Kumar, Fan Yang, Yaochao Zheng, Yunqi Li, Yao Yao, Nabil F. Saba, Yong Teng   +9 more
wiley   +1 more source

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025). [PDF]

Clin Transl Oncol
Garcia-Saenz JA, Lopez-Barajas IB, Echavarria I, Gonzalez CH, Vila MM, Antón FM, Pernas S, Cajal TRY, Ribelles N, Ezquerra MB.   +9 more
europepmc   +1 more source

Combining Spatial Multi‐Omics Data to Decipher Spatial Domains and Elucidate Cell Heterogeneity Based on Self‐Supervised Graph Learning

Advanced Science, EarlyView.
A self‐supervised multi‐view graph fusion framework integrates spatial multi‐omics, excelling in domain identification and denoising. It reconstructs spatial pseudo‐expression, jointly analyzes multi‐omics data, infers RNA velocity, predicts spatial omics features from single‐cell multi‐omics, and detects spatially dark genes and transcription factors,
Yuejing Lu, Rui Qiao, Ying Li, Junhong Li, Nuoya Yue, Jing Ge, Jiao Wang, Luonan Chen, Peiluan Li   +8 more
wiley   +1 more source

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. [PDF]

Nat Commun
Zhang P, Sun T, Wang Y, Li W, Tong Z, Phadke S, Feinstein T, Ma W, Guo P, Zhang M, Yue Y, Xu B.   +11 more
europepmc   +1 more source

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial. [PDF]

Nat Commun
Zhou J, Wu X, Du Y, Xiao J, Kang X, Chen J, Wang X, Tai Y, Bian L, Zhang S, Pang Z, Li Y, Jiang Z, Xu X, Wang T.   +14 more
europepmc   +1 more source

Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: a multicenter real-world study. [PDF]

Am J Transl Res
Zhang Y, Yang C, Jia Y, Luo R, Wang J, Han M, Liu Y, Wang X, Shi L, Yang J, Yu L, Zhang W, Niu F, Ma L.   +13 more
europepmc   +1 more source

Relationship Between Netrin-1 Staining and Neoadjuvant Treatment Response in HER2-Positive Locally Advanced Breast Cancer. [PDF]

Cancer Manag Res
Gülbağcı B, Çakırsoy Çakar G, Küçükarda A, Çavdar E, Hacıbekiroğlu I.   +4 more
europepmc   +1 more source

Advanced Breast Cancer

Oncology Times, 2007
openaire   +2 more sources

Low dose abemaciclib in heavily treated hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. [PDF]

Am J Cancer Res
Lu YR, Liu CT, Wu SC, Wu CC, Huang SY, Tsai CH, Chen YH.   +6 more
europepmc   +1 more source